Project Grant HT94252510908
Award Date
9/1/25
Completion Date
8/31/29
Dollars Obligated
$2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
This federal Project Grant award of $564,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by The Institute For Cancer Research (ICR) to explore the role of the MUL1 gene in prostate cancer development. The award period runs from May 1, 2025 to April 30, 2027. ICR, a non-profit research organization, will perform this advanced biomedical research to help transform healthcare for military service...
This federal Project Grant award of $749,996.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The research aims to uncover therapeutic vulnerabilities and deliver new treatments to improve clinical outcomes for lethal prostate cancer. The grant funds a 4-year research initiative from August 1, 2025 to July 31, 2029 to advance the...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
The Institute For Cancer Research was awarded a $188,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on April 15, 2024, supports research to exploit adenosine signaling in the tumor microenvironment to boost kidney cancer immunotherapy. This work is intended to transform health care for military service members and the public through innovative and impactful cancer research. The...
This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
The Institute For Cancer Research, a non-profit research organization and subsidiary of Temple University, was awarded a $534,445 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer, with a project period from August 1, 2023 to July 31, 2026. The Institute For Cancer Research has extensive...
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical research...
The Institute For Cancer Research has been awarded a $940,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct a mouse model study of epigenetic events in melanomagenesis. This 3-year grant, with a period of performance from July 1, 2024 to June 30, 2027, will enable the non-profit research organization to investigate the underlying epigenetic mechanisms driving the development of melanoma. As a prime grantee, The...
The Department of the Army Medical Command awarded a $699,534 project grant to the Institute of Cancer Research: Royal Cancer Hospital under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research on B7-H3 (CD276) as a therapeutic target in lethal prostate cancers. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...